Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial
This study was sponsored by Paratek Pharmaceuticals, Inc. This study described herein has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), under Contract No. 75A50120C00001. The contract and federal funding are not an endorsement of the study results, products, or company.
Authors
- Keith S. Kaye (ORCID: https://orcid.org/0000-0003-2051-1732)
- Iryna Hovbakh
- Courtney Kirsch
- Daniel Deck
- Surya Chitra (ORCID: https://orcid.org/0000-0002-5682-9200)
- Karan Soni
- Diane Anastasiou
- Stephen Villano
- Amy Manley
- Thomas M. File (ORCID: https://orcid.org/0009-0009-6080-467X)
- Kushagra Gupta (ORCID: https://orcid.org/0009-0007-9179-9207)
- Skliarov Ihor
- Vakhtang Katsarava
Institutions
- Rutgers, The State University of New Jersey (US)
- Summa Health System (US)
- Johnson University (US)
- Kharkiv State Academy of Culture (UA)
- Paratek Pharmaceuticals (United States) (US)
- Mir Technology Holdings (Turkey) (TR)
- Tbilisi State Medical University (GE)
- Northeast Ohio Medical University (US)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103656
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35